24/06/2022 (Agence Europe) – The European Medicines Agency (EMA) recommended, on Thursday 23 June, a conditional marketing authorisation for the SARS-CoV-2 vaccine developed by the firm Valneva. This developed inactivated whole virus vaccine is the sixth vaccine recommended by the EMA. The vaccine is currently recommended for adults between the ages of 18 and 50. The EMA states that the vaccine dossier contains the results of an immunobridging trial. Placebo-controlled efficacy trials...